Empowered Funds LLC Has $5.82 Million Stake in ADMA Biologics Inc $ADMA

Key Points

• Empowered Funds LLC reduced its stake in ADMA Biologics by 11.5%, now holding 293,227 shares valued at approximately $5.82 million.
• ADMA Biologics reported a quarterly earnings per share (EPS) of $0.15, surpassing estimates, with a revenue of $121.98 million, a 13.8% increase from the previous year.
• Institutional investors own 75.68% of ADMA Biologics, indicating significant financial backing from hedge funds and other large entities.

Empowered Funds LLC trimmed its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 11.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 293,227 shares of the biotechnology company's stock after selling 37,982 shares during the quarter. Empowered Funds LLC owned about 0.12% of ADMA Biologics worth $5,818,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Cetera Investment Advisers increased its position in ADMA Biologics by 1.3% during the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock worth $1,002,000 after buying an additional 670 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of ADMA Biologics by 1.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock valued at $1,323,000 after purchasing an additional 711 shares during the last quarter. GF Fund Management CO. LTD. grew its position in shares of ADMA Biologics by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company's stock valued at $120,000 after purchasing an additional 1,089 shares during the last quarter. Journey Strategic Wealth LLC grew its position in shares of ADMA Biologics by 6.6% in the first quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company's stock valued at $354,000 after purchasing an additional 1,102 shares during the last quarter. Finally, KBC Group NV grew its position in shares of ADMA Biologics by 11.5% in the first quarter. KBC Group NV now owns 11,217 shares of the biotechnology company's stock valued at $223,000 after purchasing an additional 1,154 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Trading Up 2.2%

Shares of NASDAQ:ADMA opened at $16.11 on Friday. The company has a market cap of $3.84 billion, a P/E ratio of 18.73 and a beta of 0.54. The stock's 50-day moving average is $17.51 and its 200-day moving average is $18.94. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.01. The company had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm's revenue was up 13.8% compared to the same quarter last year. During the same period last year, the business posted $0.13 earnings per share. Equities research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Activity

In other news, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director directly owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.50% of the company's stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.